Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance

NA Terrault, ASF Lok, BJ McMahon, KM Chang… - …, 2018 - Wiley Online Library
This AASLD 2018 Hepatitis B Guidance is intended to complement the AASLD 2016
Practice Guidelines for Treatment of Chronic Hepatitis B (1) and update the previous …

Chronic hepatitis B infection: a review

LSY Tang, E Covert, E Wilson, S Kottilil - Jama, 2018 - jamanetwork.com
Importance More than 240 million individuals worldwide are infected with chronic hepatitis B
virus (HBV). Among individuals with chronic HBV infection who are untreated, 15% to 40 …

Development of a scoring system to predict hepatocellular carcinoma in Asians on antivirals for chronic hepatitis B

YC Hsu, TCF Yip, HJ Ho, VWS Wong, YT Huang… - Journal of …, 2018 - Elsevier
Background & Aims The risk of hepatocellular carcinoma (HCC) during antiviral therapy in
patients with chronic hepatitis B (CHB) is inadequately predicted by the scores built from …

[HTML][HTML] HBsAg loss with peg-interferon alfa-2a in hepatitis B patients with partial response to nucleos (t) ide analog: new switch study

P Hu, J Shang, W Zhang, G Gong, Y Li… - Journal of clinical and …, 2018 - ncbi.nlm.nih.gov
Abstract Background and Aims: Hepatitis B surface antigen (HBsAg) loss is seldom
achieved with nucleos (t) ide analog (NA) therapy in chronic hepatitis B patients but may be …

Restoration of a healthy intestinal microbiota normalizes portal hypertension in a rat model of nonalcoholic steatohepatitis

T García‐Lezana, I Raurell, M Bravo… - Hepatology, 2018 - journals.lww.com
Portal hypertension (PH) drives most of the clinical complications in chronic liver diseases.
However, its progression in nonalcoholic steatohepatitis (NASH) and its association with the …

Management of hepatitis B virus infection: 2018 guidelines from the Canadian Association for the Study of Liver Disease and Association of Medical Microbiology and …

CS Coffin, SK Fung, F Alvarez… - Canadian Liver …, 2018 - canlivj.utpjournals.press
Hepatitis B virus (HBV) infection is an important public health problem in Canada. In keeping
with evolving evidence and understanding of HBV pathogenesis, the Canadian Association …

No resistance to tenofovir alafenamide detected through 96 weeks of treatment in patients with chronic hepatitis B infection

AL Cathcart, HLY Chan, N Bhardwaj, Y Liu… - Antimicrobial Agents …, 2018 - Am Soc Microbiol
Tenofovir alafenamide (TAF) has shown equivalent efficacy and improved safety profiles for
patients with chronic hepatitis B (CHB) compared to tenofovir disoproxil fumarate (TDF) …

Medication nonadherence increases hepatocellular carcinoma, cirrhotic complications, and mortality in chronic hepatitis B patients treated with entecavir

JW Shin, SW Jung, SB Lee, BU Lee… - Official journal of the …, 2018 - journals.lww.com
OBJECTIVES: Optimal adherence to nucleoside analogue treatment is necessary to achieve
undetectable levels of hepatitis B virus (HBV) DNA in patients with chronic hepatitis B (CHB) …

Systematic review with meta‐analysis: combination treatment of regimens based on pegylated interferon for chronic hepatitis B focusing on hepatitis B surface antigen …

K Qiu, B Liu, SY Li, H Li, ZW Chen… - Alimentary …, 2018 - Wiley Online Library
Background The seroclearance of hepatitis B surface antigen (HB sAg) in patients with
chronic hepatitis B (CHB) is considered to be associated with favourable clinical outcomes …

Randomized prospective study showing the non‐inferiority of tenofovir to entecavir in treatment‐naïve chronic hepatitis B patients

K Koike, K Suyama, H Ito, H Itoh… - Hepatology …, 2018 - Wiley Online Library
Aim The study aimed to evaluate the efficacy and safety of tenofovir disoproxil fumarate
(TDF) and entecavir hydrate (ETV) in nucleos (t) ide analog (NA)‐naïve Japanese chronic …